Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Claire Long

Biogen Idec building

Biogen to expand immunology and rare disease portfolio with $1.8bn HI-Bio acquisition

The company will gain access to HI-Bio’s lead asset for immune-mediated and rare diseases

- PMLiVE

Eli Lilly and Aktis enter $1bn partnership to develop anticancer radiopharmaceuticals

Lilly will gain rights to develop Aktis’ lead programme targeting a tumour-associated antigen

- PMLiVE

Johnson & Johnson shares positive phase 3 results for Tremfya versus Stelara in Crohn’s disease

The GALAXI programme comprises three trials evaluating the IL-23 inhibitor in the IBD condition

- PMLiVE

LifeArc and King’s College London partner to accelerate treatment for motor neurone disease

The rare neurodegenerative disease affects one in every 300 people in the UK

- PMLiVE

Nurturing the power of true connections in your clinical trials

By Scott Palmer

- PMLiVE

AstraZeneca unveils plans to deliver $80bn in total revenue by 2030

The company expects to launch 20 new medicines by the end of the decade

- PMLiVE

Sanofi, Formation Bio and OpenAI announce AI collaboration to accelerate drug development

The companies will combine data, software and tuned models to bring new medicines to patients more efficiently

- PMLiVE

Study finds siblings with unique genetic defects could help progress type 1 diabetes drug search

The chronic, life-long disease affected around 8.4 million people worldwide in 2021

- PMLiVE

Unearthing value: how deeper insights into diversity can drive dollars

By Matthew Hunt

- PMLiVE

Gilead’s investigational seladelpar shows promise in primary biliary cholangitis

The company gained access to the candidate through its $4.3bn acquisition of CymaBay in March

- PMLiVE

WHO updates drug-resistant bacteria list to develop new treatments for AMR

The 2024 BPPL list includes 15 families of antibiotic-resistant bacteria

- PMLiVE

GSK’s long-acting biologic shown to reduce severe asthma attacks in phase 3 studies

Approximately 200,000 people in the UK have severe cases of the lung condition

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links